Aqueous Iodine Oral Solution

Oral solution: Aqueous Iodine Oral Solution. Additional appearance criteria are not established by the specific text reviewed. ^[1]

The source defines the oral solution and its composition. It does not provide a specific clinical indication or dosing regimen for the complete mixture. ^[1]

I: 4.75-5.25% w/v; KI: 9.5-10.5% w/v ^[1]

Protect potassium iodide raw material from light. ^[2]

Iodine is volatile at ambient temperature. ^[3]

Iodine is poorly soluble in water; KI increases solubility.
Potassium iodide is very soluble in water and freely soluble in glycerol; it solubilises iodine. ^{[2], [3]}

No numerical relative-humidity limit is given for the finished product. Prevent raw-material wetting and condensation entering the container. ^[1]

No permitted temperature excursion or freeze–thaw cycle is established. Processing and storage temperatures are stated in their respective fields. ^[1]

No finished-product pH range is specified. Do not add a pH adjuster without a supported formula change. ^[1]

KI: incompatibilities with acids, metal salts, alkaloids, chloral hydrate and potassium chlorate. ^[2]

Identity and weighing basis:
• Iodine: 50 g.
• Potassium iodide: 100 g.
• Freshly boiled and cooled purified water: q.s. ad 1000 mL.
The specified chemical forms/grades belong to the exact source formula. ^[1]

Clean long-sleeved laboratory clothing, hair covering and gloves during handling; change gloves after contamination or damage. ^{[1], [4], [5]}

Reference batch: 1000 mL. First ingredient: Iodine, 50 g. Independently check chemical form, units and every scale conversion before weighing.
Check complete dissolution and crystallisation at the selected temperature. Calculate dose volume from the exact mg/mL, not the starting tablet or stock strength. Supply a suitable oral syringe.
For the local assessment record quantity per preparation, work frequency, duration of open handling, potential exposure routes and effectiveness of controls. These are assessment inputs; no fictitious final risk score is assigned.
Release checkpoint: confirm final volume or mass at the reference temperature, intended clarity or dispersion, and specified container/closure. Do not equate grams and millilitres without a justified density. ^{[1], [8], [10]}

Before mixing: verify each ingredient’s chemical form and lot, record theoretical amounts and check equipment cleanliness. Follow the temperatures and addition sequence in the procedure below. ^{[1], [5]}

No specific experimental period was located covering the complete exact formulation, container and microbiological suitability.
Aqueous oral solution containing iodine 5% and potassium iodide 10%. Neither aw <0.6 nor preservative effectiveness for this exact formula is established. Iodine content does not replace those data.
Selected conservative general rule: up to 14 days at 2–8 °C for an aqueous form without adequately established preservation. Refrigeration must not cause precipitation, irreversible separation or other loss of suitability. If that condition fails, do not apply 14 days at room temperature; obtain specific short-use evidence.
Use-by date = the earliest allowed date from preparation plus selected period, ingredient expiries and any shorter supported limit. In-use dating never extends overall BUD. Complete the actual date for the batch after the required checks.
A default is a conservative dating limit, not experimental proof of batch stability. Its category depends on final composition, preservation and permitted temperatures. Water percentage or loss on drying does not determine aw. Document using SOP-014/F-006; use SOP-017/F-012 for specific aw evidence.
USP clarification: aw measurement is not required for every nonsterile preparation. Category assignment may use the exact composition and relevant representative examples; an uncertain or borderline formulation is best assessed by a suitable specific measurement. This edition contains no measured aw or released batch. The final preparation generally must not outlast the remaining BUD of its compounded bases/intermediates. An exception requires specific justification that physical, chemical and microbiological quality is not adversely affected. Record the final limit, intermediate preparation dates and their actual expiry dates separately. ^{[1], [7], [9], [11]}

No separately registered base is required. Any commercial vehicle remains the exact named product in the formula table. ^[1]

Balance with suitable minimum weight, mortar/pestle or homogeniser, mixing vessels, spatulas, thermometer for heated processes and volumetric equipment for mL quantities. ^[1]

Dissolve potassium iodide and iodine in 100 mL water; make up to 1000 mL with water. ^[1]

High concentration. Do not calculate doses using an assumed drops-to-mL conversion. ^[1]

Selection for local assessment: well-closed bottle compatible with the liquid. Check cleanliness, integrity, closure and material compatibility before filling. The specific monograph does not validate a particular commercial container. ^[1]

Initially dilute 25 mL to 100 mL. I: 0.1 M thiosulfate, 1 mL equals 12.69 mg I. KI: 0.05 M potassium iodate, 1 mL equals 16.60 mg KI after subtracting one quarter of the iodine-assay thiosulfate volume. The two assays use different aliquots.
Record the method, acceptance criterion, actual result and reviewer separately in F-005. A critical specification failure requires quarantine and investigation under SOP-015; retesting needs justification. ^{[1], [10]}

For the selected general ceiling: 2–8 °C, provided physical suitability and compatibility with the specific source are maintained. The 14-day rule does not apply at room temperature. ^{[1], [6], [7]}

The source requires dilution before use. Do not administer undiluted as a routine dose. ^[1]

Aqueous Iodine Oral Solution
Oral use
Quantity: ____ Batch: ____
Prepared: ____ Use by: ____
Patient / dose / frequency: ____
Storage: 2–8 °C, after confirming suitability for refrigeration.
Temperature for this batch BUD: ____ ^{[1], [6], [7]}

The numeric value is a literature reference ceiling subject to its specific conditions. No actual batch BUD has been assigned and no aw measurements have been produced. The exact formula, prerequisites, container, storage and quality evidence require approval for the actual application. The BUD clock starts when compounding begins. Use the shortest applicable supported limit and assess in-use dating separately. USP categories are a technical framework and are not presented as Greek legislation.